Table 1. The summary of the PRO-ACT dataset used in this study.
| Variable | Group/Unit | n | Mean(±SD) or % |
|---|---|---|---|
| Male:Female Ratio | 6,565 | 1.58:1 | |
| Age | Years | 6,565 | 56.22 ±11.78 |
| Race |
Caucasian | 4,803 | 73.16% |
| Unknown | 1,624 | 24.74% | |
| America Indian | 2 | 0.03% | |
| Asian | 38 | 0.58% | |
| Black | 68 | 1.04% | |
| Hispanic | 18 | 0.27% | |
| Other | 12 | 0.19% | |
| 3-month fvc percent | % | 6,186 | 79.24 ±22.61 |
| Riluzole users | 5,511/7,108 | 77.53% | |
| 3-month BMI | kg/m2 (kg/cm2 *) | 3,207 | 25.37 ±4.425 |
| overall BMI | kg/m2 (kg/cm2 *) | 3,207 | 25.37 ±4.416 |
| 3-month ALSFRS | 4,835 | 29.03 ±5.89 | |
| Overall ALSFRS | 4,838 | 26.21 ±6.38 | |
| Baseline ALSFRS | No ALSFRS_R_Total score available | 3,102 | 29.46 ± 5.96 |
| Baseline ALSFRS-R | With both ALSFRS_Total and ALSFRS_R_Total scores available | 1,736 | 38.27 ± 5.29 |
| Time between diagnosis and trial entry (Diag_delta) | Days | 2,769 | 320.19 ±356.75 |
| Time between symptom onset and trial entry (Onset_delta) | Days | 4,985 | 709.66 ±539.27 |
The ‘unknown’ data was excluded from all the calculation. The 3-month data was used for the training of our model. BMI: Body Mass Index, fvc: Forced Vital Capacity, ALSFRS: ALS Functional Rating Scale, ALSFRS-R: ALS Functional Rating Scale Revised. Note that the BMI in this dataset is calculated by using cm and kg as units for height and weight, while the conventional calculation of BMI uses m and kg as units.
*: challenge data presented in these units